Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease
Ryusuke Ae(Jichi Medical University), Ermias D. Belay(Bennett Aerospace (United States)), Teppei Sasahara(Jichi Medical University), Nobuko Makino(Jichi Medical University), Masanari Kuwabara(Jichi Medical University), Koki Kosami(Jichi Medical University), Yosikazu Nakamura(Jichi Medical University), Joseph Y. Abrams(National Center for Emerging and Zoonotic Infectious Diseases), Ryan A. Maddox(United States Department of Health and Human Services), Lawrence B. Schonberger(United States Department of Health and Human Services), Yuri Matsubara(Jichi Medical University)
Cited by 29
Related Papers
Descriptive Epidemiology of Kawasaki Disease in Japan, 2011–2012: From the Results of the 22nd Nationwide Survey
|Journal of Epidemiology|2015|339
Monkeypox Outbreak — Nine States, May 2022
|MMWR Morbidity and Mortality Weekly Report|2022|309
Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015–2016
|Pediatrics International|2019|239
Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan
|Proceedings of the National Academy of Sciences|2014|209
Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017-2018
|The Journal of Pediatrics|2020|203